PD-1/VEGF Bispecific

PD-1/VEGF bispecific is the [[Akeso|康方生物]]-anchored mechanism in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位. The episode describes a Chinese phase-3 readout where a PD-1/VEGF bispecific showed strong progression-free-survival data against [[Keytruda|K药]] in the source’s account, making the asset difficult for global pharma to ignore.

The source is careful about uncertainty. [[XiaoPTeacher|小P老师]] says the mechanism is not fully explained, with possible explanations including same-molecule synergy or tumor-local concentration. [[Merck|默沙东]] is described as publicly asking for overall-survival evidence while still acting defensively through later Chinese asset buying.

Key Claims

• PD-1/VEGF bispecifics try to combine immune-checkpoint and angiogenesis-related intervention in one molecule.
• The episode treats Akeso’s data as a major China-biotech signal, not as settled proof that the mechanism will always beat PD-1 monotherapy.
• Mechanistic uncertainty and final survival data remain important.
• The asset category is commercially strategic because it sits near PD-1 Market Saturation and Multinational Pharma Patent-Cliff Anxiety.

Connections

• Akeso / 康方生物, Merck / 默沙东, and Keytruda / K药 - source company and comparator context.
• Cancer Immune Recognition Problem - immune-treatment background.
• China Biotech Asset Repricing and Biotech License-Out Arbitrage - transaction context.
• Finite-Game Biotech Competition - mature-market differentiation frame.